A potential therapeutic target could be endostatin, which is associated with vascular manifestations in SSc and is specifically elevated in progressive SSc; it has been considered a marker of disease severity [38,62,63,64,65,66,67]. Here, COL18A1 is linked to systemic sclerosis.